Xeno Aeronautics Corp, formerly Xeno Transplants Corporation, is a biotechnology research and development company that holds a commercial license from Massachusetts General Hospital (MGH) for development in the field of xenotransplantation by Novartis Pharmaceuticals (Novartis) and its associated research entities. Xenotransplantation is defined as the transplantation of organs, cells and tissues from one species to another. The Company has one reportable segment, which is the development of products to address the shortage of human donor cells and organs for transplantation into patients. All the Company’s activities are located in the United States. The Company intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.